Identification of pro-inflammatory cytokines such as tumor necrosis factor (TNF)α, IL-17, and IL-23 as therapeutic targets allowed the development of several anti-cytokine monoclonal antibodies that revolutionized treatment of psoriasis [8]. Here, TNF is linked to psoriasis.